Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- Drug: C2L-OCT-01 PR, 20 mgDrug: C2L-OCT-01 PR, 10 or 20 mg
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00642421
- Locations
- 🇺🇸
UCLA Medical Center Division of Neurosurgery, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Kaleida Health/Diabetes Center of WNY, Buffalo, New York, United States
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
- Conditions
- Acromegaly
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00635765
- Locations
- 🇧🇾
Republican Centre for Medical Rehabilitation and Water-therapy, Minsk, Belarus
🇭🇺Semmelweis Egyetem Altalanos Orvostudomanyi, Budapest, Hungary
🇷🇴Institue of Endocrinology "C.I Parhon" Bucharest, Bucharest, Romania
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- Drug: C2L-OCT-01 PR, 30 mg
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- Ambrilia Biopharma, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00616551
- Locations
- 🇧🇾
Republican Centre for Medical Rehabilitation and Water-therapy, Minsk, Belarus
🇭🇺Semmelweis Egyetem Általános Orvostudományi, Budapest, Hungary
🇷🇴Institute of Endocrinology "C. I. Parhon" Bucharest, Bucharest, Romania